Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for DYNE-101 in Myotonic Dystrophy Type 1. The expected timing is based on the latest available company guidance and may change.
07/29/26:- HARMONIA dosing began; ACHIEVE topline data Q1 2027 and BLA Q3 2027 remain planned.
Verification
Confirm timing and program details against the company announcement or filing.